Clinical Trial Update: A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) [Phase 1]

View source ↗

Summary

Phase 1 study of PRO95780 in combination with cetuximab and irinotecan (or the FOLFIRI regimen) with bevacizumab in previously treated metastatic colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• PRO95780

Snippet

Sponsor: Genentech, Inc. | Conditions: Colorectal Cancer | Phase 1 | Status: COMPLETED